Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – FBIO
In the Mar 18 session, FBIO gained 1.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Asset sale | Positive | +2.7% | Sale of Rare Pediatric Disease Priority Review Voucher for $205 million. |
| Jan 13 | FDA approval | Positive | -7.1% | FDA approval of ZYCUBO for Menkes disease with strong survival data. |
| Dec 15 | Regulatory update | Positive | +13.3% | FDA acceptance of CUTX-101 NDA resubmission with new PDUFA date. |
| Dec 10 | Clinical results | Positive | +3.5% | Publication of Phase 1 Emrosi data showing favorable microbiological profile. |
| Nov 14 | Earnings report | Positive | +5.2% | Q3 2025 revenue growth and swing to net income with higher cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally seen positive price alignment, with 4 of 5 events showing gains on favorable updates and one divergence on FDA approval news.
Over the last several months, Fortress Biotech and its affiliates have reported several key milestones. On Nov 14, 2025, Q3 2025 results showed higher revenue and net income, helped by Journey Medical. Regulatory progress around Menkes disease included FDA acceptance of the CUTX-101 NDA resubmission on Dec 15, 2025, followed by full FDA approval of ZYCUBO on Jan 13, 2026 and a subsequent $205 million Priority Review Voucher sale announced Feb 23, 2026. Journey Medical also shared positive Emrosi Phase 1 data on Dec 10, 2025. This earnings-date announcement fits into a stream of operational and regulatory updates.
Key Terms
u.s. food and drug administration regulatory
audio webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET
SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10206557/103495af641. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
